OncoMatch/Clinical Trials/NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Is NCT05450744 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 131I-IPA for neoplastic disease.
Treatment: 131I-IPA — This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: surgery — glioblastoma
Have had prior surgery for glioblastoma
Cannot have received: systemic therapy
no systemic therapy or radiation therapy for GBM
Cannot have received: radiation therapy
no systemic therapy or radiation therapy for GBM
Cannot have received: any treatment for glioma, excluding surgery
Have had prior treatment for glioma, excluding surgery
Lab requirements
Blood counts
leukocytes ≥3,000/ml; absolute neutrophil count ≥1500/ml; platelets ≥100,000/ml; haemoglobin ≥9g/dl
Kidney function
serum/plasma creatinine ≤1.5×uln or creatinine clearance ≥50 ml/min
Liver function
total bilirubin ≤1.5×uln (≤3×uln for gilbert's syndrome); alt or ast ≤2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify